SOUTH SAN FRANCISCO, Calif., March 5 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that management will hold an investor conference call on Tuesday, March 11, 2008 at 10:30 a.m. ET/7:30 a.m. PT to discuss financial results for the fourth quarter and fiscal year ended December 31, 2007.
Individual and institutional investors can access the call via (877) 604- 9668 (U.S. and Canada) or (719) 325-4904 (international). To access the live audio webcast or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://www.sunesis.com. Please log on to Sunesis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.
About Sunesis Pharmaceuticals
Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.
CONTACT: Investors, Eric Bjerkholt, SVP, Corp. Development & Finance of
Sunesis Pharmaceuticals, Inc., +1-650-266-3717; or Media, Karen L. Bergman
or Michelle Corral of BCC Partners, +1-650-575-1509 or +1-415-794-8662
Web site: http://www.sunesis.com/
